Abstract:Introduction: Most patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) have an excellent response to chemoradiation, and trials are now investigating de-escalated treatment. However, up to 25% of patients with HPV-positive OPSCC will experience recurrence, and up to 5% will even progress through primary treatment. Currently, there are no molecular markers to identify patients with poor prognosis who would be harmed by de-escalation. Herein we report the clinical and genomic characteristics of persistent HPV-positive OPSCC after definitive platinum-based chemoradiation therapy. Methods: Patients with HPV-positive OPSCC treated with curative intent platinum-based chemoradiation between 2007 and 2017 at two institutions and with a persistent locoregional disease were included. We evaluated clinical characteristics, including smoking status, age, stage, treatment, and overall survival. A subset of five patients had tissue available for targeted exome DNA sequencing and RNA sequencing. Genomic analysis was compared to a previously published cohort of 47 treatment-responsive HPV+ OPSCC tumors after batch correction. Mutational landscape, pathway activation, and OncoGPS tumor states were employed to characterize these tumors. Results: Ten patients met the inclusion criteria. The tumor and nodal stages ranged from T1 to T4 and N1 to N2 by AJCC 8th edition staging. All patients were p16-positive by immunohistochemistry, and eight with available in situ hybridization were confirmed to be HPV-positive. The 1-year overall survival from the time of diagnosis was 57%, and the 2-year overall survival was 17%. TP53 mutations were present in three of five (60%) persistent tumors compared to 2% (one of 47) of treatment-responsive HPV-positive tumors ( p = 0.008). Other genes with recurrent mutations in persistent HPV-positive OPSCC tumors were NF1 , KMT2D , PIK3C2B , and TFGBR2 . Compared to treatment-responsive HPV-positive tumors, persistent tumors demonstrated activation of DNA Repair and p53, EMT, MYC, SRC, and TGF-beta signaling pathways, with post-treatment samples demonstrating significant activation of the PI3K-EMT-Stem pathways compared to pretreatment samples. Conclusion: Chemoradiation-resistant HPV-positive OPSCC occurs infrequently but portends a poor prognosis. These tumors demonstrate higher rates of p53 mutation and activation of MYC, SRC, and TGF-beta pathways. A comparison of tumors before and after treatment demonstrates PI3K-EMT-Stem pathways post-treatment in HPV-positive tumors with persistent disease after platinum-based chemoradiation.

Pre-radiotherapy dental status of oropharyngeal cancer patients based on HPV status in a novel radiation era

Presenting pre-radiotherapy dental status of head and neck cancer patients in the novel radiation era

The declining role of post-treatment neck dissection in human papillomavirus-associated oropharyngeal cancer

Personalizing dental screening and prevention protocols in dentulous patients with oropharyngeal cancer undergoing radiotherapy: A retrospective cohort study

Advances in testing for human papillomavirus-mediated head and neck cancer

Can we safely de-escalate HPV + oropharyngeal cancers? – A review of current practices and novel approaches

The epidemic of human papillomavirus virus-related oropharyngeal cancer: current controversies and future questions

Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma

The effect of human papillomavirus status on prognosis and local treatment strategies of T1-2N0 oropharyngeal squamous cell cancer

Nutritional Support in Head and Neck Radiotherapy Patients Considering HPV Status

Assessment of the Impact of HPV Infection on the Incidence and Prognosis of Oral Cancers

An audit of dental assessments including orthopantomography and timing of dental extractions before radiotherapy for head and neck cancer

Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer

Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy

The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer

De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies

HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

Retrospective study of survival in human papillomavirus-negative oropharyngeal squamous cell carcinoma treated with primary surgery and associated prognostic factors.

HPV-associated head and neck cancer: a virus-related cancer epidemic

Dental extractions for preradiation dental clearance and incidence of osteoradionecrosis in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland